Tozorakimab PK-PD
Indication: Chronic obstructive pulmonary disease (COPD)
Interactive tozorakimab PK/target-engagement simulator based on a published two-compartment popPK model with SC/IV dosing and Figure 5-calibrated IL-33/sST2 inhibition.
Drug Overview
Clinical Context
- Molecular Target
- IL-33
- Drug Class
- Anti-IL-33 monoclonal antibody
- Therapeutic Area
- Respiratory / Inflammatory disease
- Indication
- Chronic obstructive pulmonary disease (COPD)
- Route of Administration
- Subcutaneous / Intravenous
Model Information
- Model Type
- Two-compartment population PK / target engagement model
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Tozorakimab allows you to explore concentration-time profiles under different dosing scenarios. The underlying Two-compartment population PK / target engagement model model characterizes the pharmacokinetics of this anti-il-33 monoclonal antibody following subcutaneous / intravenous administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Tozorakimab PK simulator?
This is a free, interactive pharmacokinetic simulator for Tozorakimab used in Chronic obstructive pulmonary disease (COPD). It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Tozorakimab belong to?
Tozorakimab is classified as a Anti-IL-33 monoclonal antibody that targets IL-33. It is used in the Respiratory / Inflammatory disease therapeutic area.
What route of administration does this model simulate?
This simulator models Subcutaneous / Intravenous administration of Tozorakimab. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Two-compartment population PK / target engagement model model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Ready to Simulate?
Launch the Tozorakimab simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community